Cargando…
Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol
COVID-19 increases the risk of atrial fibrillation (AF) and thrombotic complications, particularly in severe cases, leading to higher mortality rates. Anticoagulation is the cornerstone to reduce thromboembolic risk in patients with AF. Considering the risk of hepatotoxicity in patients with severe...
Autores principales: | Cerezo-Manchado, Juan José, Meca Birlanga, Olga, García de Guadiana Romualdo, Luis, Gil-Ortega, Ignacio, Martínez Francés, Antonio, Iturbe-Hernandez, Teodoro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798364/ https://www.ncbi.nlm.nih.gov/pubmed/35145555 http://dx.doi.org/10.7573/dic.2021-9-4 |
Ejemplares similares
-
Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol
por: Iturbe-Hernandez, Teodoro, et al.
Publicado: (2020) -
Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry
por: Cerezo Manchado, Juan José, et al.
Publicado: (2023) -
The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality
por: Cerezo Manchado, Juan Jose, et al.
Publicado: (2020) -
Cost of dabigatran for atrial fibrillation
por: Gage, Brian F
Publicado: (2011) -
Anibal
por: Baker, George Philip, 1879-
Publicado: (1963)